Warfarin therapy: Evolving strategies in anticoagulation

American Family Physician

Volumn 59, Issue 3, 1999, Pages 635-646

  Horton, Jon D ^a   Bushwick, Bruce M ^a  

^a York Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALLOPURINOL; AMIODARONE; ANTIFUNGAL AGENT; ANTITHYROID AGENT; BARBITURIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR 7; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CIMETIDINE; CORTICOSTEROID; DANAZOL; DIFLUNISAL; DISULFIRAM; FLUVOXAMINE; FLUVOXAMINE MALEATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; METRONIDAZOLE; NALIDIXIC ACID; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PAROXETINE; PHENYTOIN; PROPAFENONE; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL STANDARD UNIT; PRACTICE GUIDELINE; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; RISK FACTORS; WARFARIN;

EID: 0033082809     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. National prescription audit: physician specialty report, dispensed data. Plymouth Meeting, Pa.: IMS America, 1998.
2. Retail perspective and provider perspective audit. Plymouth Meeting, Pa.: IMS America, 1998.
3. Agency for Health Care Policy and Research. Life-saving treatments to prevent stroke underused. Press release, September 1995. Retrieved November 1998 from the World Wide Web at http://www.ahcpr.gov/ news/press/stroke.htm.
4. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(4 Suppl):231S-46S.
5. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biologic prosthetic heart valves. Chest 1995;108(4 Suppl):371S-9S [Published erratum in Chest 1996;109:592].
6. Levine HJ, Pauker SG, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1995; 108(4 Suppl):360S-70S.
7. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336:393-8.
8. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995;108(4 Suppl):352S-9S.
9. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.
10. Majerus PW, Broze GJ, Miletich JP, Tollefsen DM. Anticoagulant thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:1347-51.
11. Porter RS, Sawyer WT, Lowenthal DT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. 2d ed. Spokane, Wash.: Applied Therapeutics, 1986:1057-104.
12. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffatt K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6.
13. Gürwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-4.
14. Thomas P, Fennerty A, Backhouse G, Bentley DP, Campbell IA, Routledge PA. Monitoring effects of oral anticoagulants during treatment with heparin. Br Med J [Clin Res] 1984;288;191.
15. Ansell JE. Oral anticoagulant therapy - 50 years later. Arch Intern Med 1993;153:586-96.
16. Carter BL. Therapy of acute thromboembolism with heparin and warfarin. Clin Pharm 1991;10:503-18.
17. Norton JL, Gibson DL. Establishing an outpatient anticoagulation clinic in a community hospital. Am J Health Syst Pharm 1996;53:1151-7.
18. Wittkowsky AK. Generic warfarin: implications for patient care [Editorial]. Pharmacotherapy 1997;17: 640-3.
19. Richton-Hewett S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988;148:806-8.
20. Routledge PA, Chapman DH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol 1979; 8:243-7.
21. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108(4 Suppl):276S-90S.
22. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-28.
23. Landefeld CS, Rosenblatt MW, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52.
24. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994;154:1443-8.
25. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57 [Published erratum in Arch Intern Med 1994;10:2254].
26. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993;118:511-20.
27. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991;229:351-5.
28. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-9.
29. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.
30. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
31. Adjusted-dose warfarin versus, low-intensity, fixed-dose warfarin plus aspirin for high-risk, patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633-8.
32. Havrda DE, Anderson JR, Talbert RL. Thrombosis In: Pharmacotherapy self assessment program module 1 cardiovascular. Kansas City, MS.: American College of Clinical Pharmacy; 1998. Retrieved September 1998 from the World Wide Web at http:www.accp.com/psap3-des.html.
33. Warfarin. In: Drugdex. Englewood, Colo.: Micromedex Inc., 1998.